TNIB Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech,

New Post Public Reply Private Reply Replies (2) Message Board

Oct 11, 2012 at 3:17 PM

[b]TNIB >Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer[/b]

2012-10-11 07:30 ET - News Release

NEW YORK, NY and POTOMAC MD -- (Marketwire) -- 10/11/12

TNI BioTech, Inc. (PINKSHEETS: TNIB), a public company operating in the biotech sector, announced today the signing of an agreement with Pharmaceutical Care Consultants of South Florida, d/b/a Skip's Pharmacy. Under the agreement, Dr. Henry "Skip" Lenz and Phil Giordano will join the company as heads of Quality Control and Quality Assurance for TNIB's pharmaceutical plant in Managua, Nicaragua. Dr. Lenz will be responsible for leading the company's global manufacturing development.

Dr. Lenz will join the company's executive leadership team, and report to Noreen Griffin, CEO and Dr. Eugene Youkilis, President of TNI BioTech, Inc. As the company's Quality Control Officer, Dr. Lenz will be responsible for assuring all manufacturing meets cGMP standards. Dr. Lenz has held senior management positions in quality control, quality assurance and production for several international manufacturers. In addition, Dr. Lenz held senior clinical research pharmacist positions with both domestic and international clinical research groups, including Senior Researcher at Key Pharmaceuticals in charge of the Research Division. Dr. Lenz founded and ran a contract research company producing over 10 patents before being acquired by a mid-sized manufacturing company. Over the last fifteen years Dr. Lenz has set his sights on relieving HIV/AIDS by participating in clinical applications of several novel therapies.

Dr. Lenz is a graduate of The Massachusetts College of Pharmacy and the University of Florida. Currently, he owns Pharmaceutical Care Consultants of South Florida d/b/a Skip's Pharmacy in Boca Raton, Florida with his partner Phil Giordano. Skip's Pharmacy is dedicated to providing the highest quality and optimum pharmaceutical care through its unique ability to formulate and compound drugs specifically to meet patient's needs. Skip's Pharmacy has been the leading outlet for the supply of LDN for over ten years.

Noreen Griffin, TNI BioTech, Inc.'s CEO, noted the company's hiring of Dr. Lenz and his partners continues to reflect TNI BioTech's commitment to deliver a quality product and to become a world-class leader in innovative therapeutics for patients afflicted with autoimmune and infectious diseases such as cancer and HIV/AIDS.

Dr. Lenz stated, "I was pleased to see that TNIB was taking the manufacturing and distribution of IRT-103 (LDN) seriously. It is important that IRT-103 (LDN), a treatment that has done so much good for some any people, be available at a quality and a price that benefits everyone."

About TNI Biotech, Inc.

TNI BioTech, Inc., is a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are re-infused back into the patient where they combat and destroy tumor cells.

Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:

Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
As an adjunct to antibiotics in the treatment of infectious diseases;
In cancer patients undergoing chemotherapy, radiation treatments or surgery;
Patients with AIDS, in combination with retroviral drug therapy; and
In wound healing or herpes viral infections.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.

See http://www.tnibiotech.com for more information.

Contact:

Global Investment Media

Phone: 310-353-6277

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

JEM Global Brings Smart Outdoor Lights to Walmart

Walmart's New Lighting Surprise for the Holidays Throw your boring old holiday lights out the window because JEM Global's just teamed up with Walmart to unleash the Monster Smart 150-Foot RGBIC + Multi-White Permanent Outdoor Lights. Yeah, that means a facelift for your house without breaking the bank—$114.99 to be exact, right off the virtual shelves on Walmart.com and...

Telecom Argentina's 2026 Financial Rollercoaster Ride

Analyzing Telecom Argentina's Financial Turmoil Telecom Argentina's nine-month stretch of 2026 wasn’t a smooth sail by any stretch. The powerhouse saw a consolidated net loss of P$56,615 million for the third quarter while bagging a net income of P$862,959 million across the broader period. Talk about volatility. It's a classic case of juggling financial fire,...

Strategic Fit Key in HR Tech Decisions, Claims Study

Choosing the Right Learning Tools for Strategic Growth Trying to solve today's HR challenges with yesterday's tools is like using a hammer to fix your computer. In the rapidly evolving landscape of learning technologies, McLean & Company is passing along a crucial piece of advice: focus on strategy, not just on loading up features. Nailing Down Organizational Priorities...

Longsys and Lexar Push Boundaries in Edge AI Storage

Longsys and Lexar: A Revolution in Storage Ah, the tech world—it's like a fast-moving express train you just can't afford to miss. Longsys and its sidekick Lexar are in the spotlight this time, and boy, they've got some head-turning announcements. At electronica 2026 in Munich, they're playing the storage game hard. From industrial-grade mSSD to automotive solutions,...

A New Era of Loyalty Commerce The winds are changing in the loyalty game, and it's about time someone shook things up. Squeez has teamed up with Qentelli, thanks to a $1 million investment, to kick-start this next wave of commerce. And boy, it's not just about money—it's like combining brains with brawn. Squeez isn't just offering loyalty programs anymore; they're...

Wyalusing Valley, Wysox Centers Change Ownership

A New Chapter for Pennsylvania's Childcare Gems In the often unpredictable world of childcare services, a shift is happening in Pennsylvania that has John and Robyn Lacy stepping back after two decades of dedicated service. The Wyalusing Valley Children's Center and Wysox Children's Center have found a new home in the hands of a private investor, signifying a significant...

Poland Bolsters Defense with SATIM SAR Software

Poland's Defense Strategy Enters a New Era Scrap what you know about sitting around waiting for intelligence. Poland's Ministry of National Defence has jumped on a new gig with SATIM to revolutionize how they handle satellite radar imagery. This ain't child's play—this deal's all about putting the pedal to the metal with SAR, or synthetic aperture radar, analytics under...

LITEON Unveils Edge AI and Power Solutions at Electronica

Redefining AI Infrastructure with LITEON Strolling through the electronica 2026 event in Munich, you can't help but notice LITEON flexing its muscles in the AI space. No fluffy marketing talk here—it's all about hard-core tech stats and future-proofing AI infrastructure. They're touting AI innovations that scale from cloud juggernauts to nimble edge applications, which...

Latch Reports Q3 2026: Software Shines Amid Losses

Latch's Performance: A Crunch Between Software and Setbacks The stock ticker might say "LTCH," but lately, Latch Inc. is feeling more like "OUCH" for investors. While they're trumpeting a solid 18% boost in software revenue, the numbers tell a mixed story. Yeah, their software side is singing, but hardware and services took a nosedive, dragging total revenue down 18.9%...

EPIC Players Seeks Sponsors for 2027 Gala & Seasons

Shining the Spotlight on Neurodivergent and Disabled Artists The curtains are about to rise for EPIC Players' 10th Anniversary Gala, and folks, it's more than just a party; it's a cause worth championing. Set for April 7, 2027, at New York's City Winery, this event is an invitation for brands to spotlight their support for Neurodivergent and Disabled artists. If you've...